ZIM Laboratories Limited has notified the stock exchanges of the completion of a European Good Manufacturing Practices (EU GMP) inspection at its manufacturing facility. The inspection, carried out by German and Portuguese regulatory authorities, was conducted from May 4, 2026 to May 7, 2026, marking a significant step in the company's EU GMP compliance process. This update follows the company's earlier intimation dated August 1, 2025, regarding the EU GMP Inspection Outcome.

Inspection Details

The audit was held at ZIM Laboratories' manufacturing facility situated at B-21/22, MIDC Area, Kalmeshwar – 441 501, District Nagpur, Maharashtra. The inspection was undertaken as part of the European Good Manufacturing Practices compliance process, with the German and Portuguese regulatory authorities jointly overseeing the audit.

Key details of the inspection are outlined below:

Regulatory Compliance Commitment

ZIM Laboratories has stated that it remains committed to the highest standards of quality and regulatory compliance across all its operations. The company has also indicated that it will continue to update stakeholders on the progress of this matter as appropriate.

The disclosure was made under Regulation 30 and was filed with both BSE Limited and the National Stock Exchange of India Limited. The intimation was signed by Piyush Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), on May 8, 2026.

Zim laboratories promoter Zulfiqar Kamal has submitted a regulatory disclosure to stock exchanges declaring that no encumbrance of shares was made during the financial year ended March 31, 2026. The disclosure was filed on April 1, 2026, with both BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance Declaration

The disclosure was made pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. In his formal declaration, Kamal stated that he, along with persons acting in concert, have not made any encumbrance of shares, either directly or indirectly, during the specified financial year.

Stock Exchange Notification

The disclosure was simultaneously submitted to multiple regulatory bodies and stakeholders. The communication was addressed to BSE Limited's Compliance Department and National Stock Exchange of India Limited's Listing Compliance Department. Additionally, the Audit Committee of ZIM Laboratories Limited was included in the disclosure process.

Promoter Declaration Scope

The declaration encompasses a comprehensive coverage of potential encumbrance activities. Kamal's statement specifically covers both direct and indirect encumbrances, ensuring complete transparency regarding share-related transactions. The disclosure also extends to include any persons acting in concert with the promoter, providing a broader scope of compliance coverage.

This regulatory filing demonstrates the company's commitment to maintaining transparency and adhering to SEBI's disclosure requirements for substantial shareholding and takeover regulations.